Literature DB >> 8755652

Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure.

B I Levy1, J Benessiano, D Henrion, L Caputo, C Heymes, M Duriez, P Poitevin, J L Samuel.   

Abstract

Angiotensin II (Ang II) is both a vasoactive and a potent growth-promoting factor for vascular smooth muscle cells. Little is known about the in vivo contribution of AT1 and AT2 receptor activation to the biological action of Ang II. Therefore, we investigated the effect of AT1 or AT2 subtype receptor chronic blockade by losartan or PD123319 on the vascular hypertrophy in rats with Ang II-induced hypertension. Normotensive rats received for 3 wk subcutaneous infusions of Ang II (120 ng/kg per min), or Ang II + PD 123319 (30 mg/kg per d), or Ang II + losartan (10 mg/kg per d) or PD 123319 alone, and were compared with control animals. In normotensive animals, chronic blockade of AT2 receptors did not affect the plasma level of angiotensin II and the vascular reactivity to angiotensin II mediated by the AT1 receptor. Chronic blockade of AT1I in rats receiving Ang II resulted in normal arterial pressure, but it induced significant aortic hypertrophy and fibrosis. Chronic blockade of AT2 receptors in Ang II-induced hypertensive rats had no effect on arterial pressure, but antagonized the effect of Ang II on arterial hypertrophy and fibrosis, suggesting that in vivo vasotrophic effects of Ang II are at least partially mediated via AT2 subtype receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755652      PMCID: PMC507445          DOI: 10.1172/JCI118807

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Non-invasive estimate of the mechanical properties of peripheral arteries from ultrasonic and photoplethysmographic measurements.

Authors:  Y Tardy; J J Meister; F Perret; H R Brunner; M Arditi
Journal:  Clin Phys Physiol Meas       Date:  1991-02

2.  Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II.

Authors:  G H Gibbons; R E Pratt; V J Dzau
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  Angiotensin-II receptor subtypes in fetal tissue of the rat: autoradiography, guanine nucleotide sensitivity, and association with phosphoinositide hydrolysis.

Authors:  K Tsutsumi; C Strömberg; M Viswanathan; J M Saavedra
Journal:  Endocrinology       Date:  1991-08       Impact factor: 4.736

4.  Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs.

Authors:  P C Wong; S D Hart; J V Duncia; P B Timmermans
Journal:  Eur J Pharmacol       Date:  1991-09-24       Impact factor: 4.432

5.  Chronic treatment with the angiotensin I converting enzyme inhibitor, perindopril, protects in vitro carbachol-induced vasorelaxation in a rat model of vascular calcium overload.

Authors:  D Henrion; J M Chillon; C Capdeville-Atkinson; M Vinceneux-Feugier; J Atkinson
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

6.  Differential regulation of angiotensin peptide levels in plasma and kidney of the rat.

Authors:  D J Campbell; A C Lawrence; A Towrie; A Kladis; A J Valentijn
Journal:  Hypertension       Date:  1991-12       Impact factor: 10.190

7.  Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2).

Authors:  P C Wong; S D Hart; A M Zaspel; A T Chiu; R J Ardecky; R D Smith; P B Timmermans
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

8.  Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-beta.

Authors:  G A Stouffer; G K Owens
Journal:  Circ Res       Date:  1992-04       Impact factor: 17.367

9.  Reversal of low dose angiotension hypertension by angiotensin receptor antagonists.

Authors:  G J Smits; J P Koepke; E H Blaine
Journal:  Hypertension       Date:  1991-07       Impact factor: 10.190

10.  Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats.

Authors:  S P Tofovic; A S Pong; E K Jackson
Journal:  Hypertension       Date:  1991-12       Impact factor: 10.190

View more
  32 in total

Review 1.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 3.  Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?

Authors:  R Komers; S Anderson
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 4.  Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance.

Authors:  G H Gibbons
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 5.  Angiotensin II type-2 receptor-specific effects on the cardiovascular system.

Authors:  Ying Li; Xiao-Hui Li; Hong Yuan
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

Review 6.  Molecular mechanisms of angiotensin II-induced vascular injury.

Authors:  Marta Ruiz-Ortega; Monica Ruperez; Vanesa Esteban; Jesús Egido
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

7.  Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan.

Authors:  M Turcani; H Rupp
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

8.  Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.

Authors:  A Koïtka; Z Cao; P Koh; A M D Watson; K C Sourris; L Loufrani; A Soro-Paavonen; T Walther; K J Woollard; K A M Jandeleit-Dahm; M E Cooper; T J Allen
Journal:  Diabetologia       Date:  2009-12-03       Impact factor: 10.122

9.  A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy.

Authors:  Takaaki Senbonmatsu; Takako Saito; Erwin J Landon; Otsu Watanabe; Edward Price; Richard L Roberts; Hans Imboden; Trinita G Fitzgerald; F Andrew Gaffney; Tadashi Inagami
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

10.  Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma.

Authors:  Kazuyuki Hirooka; Fumio Shiraga
Journal:  Clin Ophthalmol       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.